Holen Sie sich die Stockscreener-App
28.80
0.73%
0.21
Schlusskurs vom Vortag:
$28.59
Offen:
$28.6
24-Stunden-Volumen:
795.24K
Relative Volume:
0.88
Marktkapitalisierung:
$1.73B
Einnahmen:
$439.00K
Nettoeinkommen (Verlust:
$-105.64M
KGV:
-16.00
EPS:
-1.8
Netto-Cashflow:
$-60.70M
1W Leistung:
-1.64%
1M Leistung:
+7.34%
6M Leistung:
+16.27%
1J Leistung:
-38.06%
1-Tages-Spanne:
$28.39
$30.19
1-Wochen-Bereich:
$27.67
$30.23
52-Wochen-Spanne:
$21.73
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
28.80 | 1.72B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-10 | Eingeleitet | Stifel | Buy |
| 2025-09-10 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-11 | Eingeleitet | Raymond James | Outperform |
| 2024-12-03 | Bestätigt | BTIG Research | Buy |
| 2024-12-03 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-06 | Eingeleitet | Stifel | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-03-21 | Eingeleitet | BTIG Research | Buy |
| 2024-03-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
What analysts say about Janux Therapeutics Inc stockCurrency Fluctuation Impact & Breakout Stock Alerts - earlytimes.in
First Week of JANX January 2026 Options Trading - Nasdaq
How strong is Janux Therapeutics Inc. stock balance sheet2025 Top Decliners & Free Verified High Yield Trade Plans - newser.com
Relative strength of Janux Therapeutics Inc. in sector analysisJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Why Janux Therapeutics Inc. stock remains undervaluedPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
Is the RiskReward Ratio Favorable for Prima Agro Limited in YEARSell Signals and Alerts & Outstanding Growth Opportunities - earlytimes.in
Wolfe Research Initiates Coverage of Janux Therapeutics (JANX) with Peer Perform Recommendation - Nasdaq
Understanding the Setup: (JANX) and Scalable Risk - news.stocktradersdaily.com
Wolfe Research initiates Janux Therapeutics stock with Peerperform rating By Investing.com - Investing.com Canada
Janux Therapeutics initiated with a Peer Perform at Wolfe Research - TipRanks
Jones Trading Remains Bullish on Janux Therapeutics (JANX) Amid Promising Developments in Prostate Cancer Program - Finviz
Is Janux Therapeutics Inc. stock a safe buy before earningsJuly 2025 Breakouts & Real-Time Volume Analysis - newser.com
Janux therapeutics CBO Meyer sells $99990 in shares By Investing.com - Investing.com South Africa
10 Best Small-Cap Biotech Stocks to Buy According to Analysts - Insider Monkey
Janux therapeutics CBO Meyer sells $99990 in shares - Investing.com
Will Janux Therapeutics Inc. price bounce be sustainableEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Volume spikes in Janux Therapeutics Inc. stock – what they meanPortfolio Return Report & Accurate Buy Signal Notifications - newser.com
Can Janux Therapeutics Inc. stock surprise with earnings upsideWeekly Gains Summary & Stepwise Trade Signal Implementation - newser.com
Positive Outlook on Janux Therapeutics Inc. Driven by Promising Prostate Cancer Developments and Strong Financial Position - TipRanks
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
Cantor Fitzgerald Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX) - The Globe and Mail
Why Janux Therapeutics (JANX) Draws Analyst Optimism Despite Widening Year-to-Date Losses - Yahoo Finance
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Janux Therapeutics Reports Strong Financial Position Amid Clinical Advancements - MSN
Janux Therapeutics price target raised to $46 from $45 at Stifel - MSN
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):